These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31939146)

  • 1. Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.
    Rinciog C; Diamantopoulos A; Gentilini A; Bondue B; Dahlqvist C; Froidure A; Wuyts WA; Soulard S
    Pharmacoecon Open; 2020 Sep; 4(3):449-458. PubMed ID: 31939146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France.
    Clay E; Cristeau O; Chafaie R; Pinta A; Mazaleyrat B; Cottin V
    J Mark Access Health Policy; 2019; 7(1):1626171. PubMed ID: 31275535
    [No Abstract]   [Full Text] [Related]  

  • 4. Health economic evaluation in idiopathic pulmonary fibrosis in France.
    Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
    Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
    Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
    Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
    [No Abstract]   [Full Text] [Related]  

  • 8. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
    Corral M; Chang E; Broder MS; Gokhale S; Reddy SR
    J Comp Eff Res; 2020 Sep; 9(13):933-943. PubMed ID: 32851849
    [No Abstract]   [Full Text] [Related]  

  • 9. Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Davis S; Rafia R; Carroll C; Hamilton J; Essat M
    Pharmacoeconomics; 2019 Jun; 37(6):763-775. PubMed ID: 30345464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapies for treatment of idiopathic pulmonary fibrosis: a systematic review, Bayesian network meta-analysis, and cost-effectiveness analysis.
    Zhao C; Yin Y; Zhu C; Zhu M; Ji T; Li Z; Cai J
    EClinicalMedicine; 2023 Jul; 61():102071. PubMed ID: 37434745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia.
    Cox IA; de Graaff B; Corte TJ; Glaspole I; Chambers DC; Moodley Y; Teoh A; Walters EH; Palmer AJ
    Aust Health Rev; 2021 Dec; 45(6):718-727. PubMed ID: 34706811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
    Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
    Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.
    Skandamis A; Kani C; Markantonis SL; Souliotis K
    J Drug Assess; 2019; 8(1):55-61. PubMed ID: 31044096
    [No Abstract]   [Full Text] [Related]  

  • 19. Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases.
    Liu J; Wang F; Hong Y; Luo F
    Heliyon; 2024 Apr; 10(8):e29266. PubMed ID: 38655311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data.
    Khan MA; Sherbini N; Alyami S; Al-Harbi A; Al-Ghamdi M; Alrajhi S; Rajendram R; Al-Jahdali H
    Ann Thorac Med; 2023; 18(1):45-51. PubMed ID: 36968327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.